Welcome to our dedicated page for AETHLON MEDICAL news (Ticker: $AEMD), a resource for investors and traders seeking the latest updates and insights on AETHLON MEDICAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AETHLON MEDICAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AETHLON MEDICAL's position in the market.
Rhea-AI Summary
Aethlon Medical partners with Santersus AG to conduct pre-clinical studies on NucleoCapture and HemoNucleoCapture devices for potential synergies with Hemopurifier® in cancer and kidney transplant settings, aiming to remove harmful substances from blood and biological fluids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Aethlon Medical, Inc. reports financial results for Q3 2023, updates on Hemopurifier® development, and recent developments. The company received clearance for a phase 1 trial in India and is exploring applications in oncology and organ transplants. The financial results show a cash balance of $8.0 million, with operating expenses increasing due to payroll expenses and a net loss of $3.6 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
-
Rhea-AI Summary
Aethlon Medical, Inc. (AEMD) will release financial results for its fiscal third quarter ended December 31, 2023, on February 14, 2024. The company will host a conference call to review financial results and corporate developments. Interested parties can register for the conference and access a replay of the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
News
Rhea-AI Summary
Aethlon Medical, Inc. (Nasdaq: AEMD) reported financial results for its fiscal second quarter, highlighted by updates on the Hemopurifier® research and clinical development, including clearance for a phase 1 trial in India, and changes in executive leadership. The company also addressed the disruption in the Hemopurifier supply and its financials, showing a decrease in net loss from $3.8 million to $3.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
-
Rhea-AI Summary
Aethlon Medical, Inc. (Nasdaq: AEMD) appoints James B. Frakes as Interim Chief Executive Officer and member of the Board of Directors, replacing Charles J. Fisher, Jr. M.D. Guy Cipriani is appointed as the Company's Chief Operating Officer, and the resignation took effect on November 7, 2023. The company is set to initiate a phase 1 safety, feasibility, and dose-finding trial of the Hemopurifier in patients with solid tumors, having received clearance from the Drug Controller General of India (DCGI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
-
Rhea-AI Summary
Aethlon Medical, Inc. will release its financial results for the second quarter ended September 30, 2023, on November 14, 2023, at 4:15 p.m. ET. A conference call will be held at 4:30 p.m. ET to review the results and recent corporate developments. Interested parties can register for the conference call online or dial in using the provided numbers. A replay of the call will be available until December 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
Rhea-AI Summary
Aethlon Medical has received clearance from the DCGI in India to conduct a phase 1 trial of its Hemopurifier® in patients with solid tumors. The trial will evaluate the safety and feasibility of the treatment in patients receiving Keytruda® or Opdivo® therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
-
Rhea-AI Summary
Aethlon Medical approves 1-for-10 reverse stock split, allowing the company to meet listing requirements and remain trading on Nasdaq. Clinical programs and expansion plans can be supported with access to capital markets. Each ten shares will be converted into one share, resulting in approximately 2.5 million shares issued and outstanding. Common stock will trade under a new CUSIP number, effective October 5, 2023. All warrants, stock options, and restricted stock units will be adjusted proportionally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
791.36%
Tags
-
Rhea-AI Summary
Aethlon Medical to present at H.C. Wainwright conference on September 12 at 4:30 PM EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
AETHLON MEDICAL INC
Nasdaq:AEMD
AEMD Rankings
AEMD Stock Data
3.29M
2.57M
1.42%
1.99%
0.72%
Analytical Laboratory Instrument Manufacturing
Manufacturing
United States of America
SAN DIEGO
About AEMD
the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.